That is a great question, I think it is dependent on a number of variables.
- Hype – often this is dictated by investors and popularity.
- Forecasted growth – This will grow in the next 12 months
- Maturity / potential of the company – This will grow in the next 12 months
I do believe that ALC has a significant re-rate in store. However, there needs to be a realisation from new investors of who/what we do at the end of the day.
A realisation is also needed on the whole Health IT sector imo.
price to sales ratio, page-2
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
